小鼠中充满希望的鼻涕喷雾疫苗提供广泛、长期的保护,防止流感、COVID-19、感冒、肺炎和过敏,仅用一剂剂量,有可能消除每年的针头,但仍需进行人类试验。 A promising nasal spray vaccine in mice offers broad, long-lasting protection against flu, COVID-19, colds, pneumonia, and allergens with just one dose, potentially eliminating annual shots, but human trials are still needed.

在小鼠身上测试的鼻涕喷雾疫苗表明,通过培训肺T细胞以维持本体免疫反应,在防止流感、COVID-19、常见的寒冷病毒、细菌肺炎和过敏方面很有希望。 A nasal spray vaccine tested in mice shows promise in protecting against flu, COVID-19, common cold viruses, bacterial pneumonia, and allergens by training lung T cells to sustain innate immune responses. 一种剂量提供了几个月的广泛保护,研究人员认为两种剂量可以提供人的长期免疫,有可能消除每年拍摄的必要性。 One dose provided several months of broad protection, with researchers suggesting two doses may offer long-term immunity in humans, potentially eliminating the need for annual shots. 这种方法模仿免疫信号,而不是针对特定的病原体,可能会使呼吸道疾病的预防发生革命性的变化。 The approach, which mimics immune signals rather than targeting specific pathogens, could revolutionize respiratory disease prevention. 虽然专家们称这是向前迈出的重要一步,但仍需进行人类试验,安全关切依然存在,最终产品可能要等多年。 While experts call it a significant step forward, human trials are still needed, safety concerns remain, and a final product is likely years away.